Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind Placebo-Controlled Study of Ataluren in Nonsense Mutation Duchenne Muscular Dystrophy With Open-Label Extension
2017-001223-49Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Ataluren with Placebo (2 arms). Primary endpoint: Slope of change in 6-minute walk distance over 72 weeks. Started Oct 2017; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2017-001223-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001223-49.